Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a ...

Sanofi (SNY, Financials) closed its previously announced deal to carve out consumer health business Opella into a standalone global leader, marking a strategic pivot toward pure-play biopharma ...

Sanofi (SNY, Financials) closed its previously announced deal to carve out consumer health business Opella into a standalone global leader, marking a strategic pivot toward pure-play biopharma ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton Dublilier & Rice, known as CD&R.

Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025. Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the ...

The FDA on Friday cleared Sanofi ’s Merilog (insulin-aspart-szjj), a biosimilar to Novo Nordisk ’s rapid-acting insulin NovoLog. Like its branded reference counterpart, Merilog is indicated to lower ...

Sanofi has provided updated financial information reflecting its decision to transfer a 50% controlling stake in Opella, its consumer healthcare division, to CD&R.